How to Avoid Cervical Stenosis After LEEP in High Grade Cervical Dysplasia?

NCT ID: NCT02500966

Last Updated: 2020-01-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

265 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-08-31

Study Completion Date

2019-01-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cervical stenosis may occur in up to 19% after conization. It is a cause of infertility and amenorrhea. This study will test a new device named DUDA Device ("Dispositivo Uterino para dilatar canal endocervical") placed just after the conization, in order to evaluate the safety, efficacy and quality of life.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This device has the potential to improve outcomes by means of a significant stenosis reduction and maintain patency of the endocervical canal to view the squamo-columnar junction (SCJ) of the cervix during follow-up of this patient.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stenosis Cervix

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DUDA device

The number of patients to be recruited in this arm will be 145. Note: The first twenty-five patients who will be included in the study will be allocated in the intervention arm to safety analysis (phase 1); after that all eligible candidates will be randomized 1:1 (phase 2).

Procedure: Loop Electrosurgical Excision Procedure (LEEP) followed by implantation of the device called DUDA (plastic device developed in barretos cancer hospital that will be placed after conization. It has 2.5 cm in length and 5mm in diameter and remains within the endocervical canal for 30 days and is set at 4 points with nonabsorbable sutures in the ectocervix.)

Group Type EXPERIMENTAL

DUDA device

Intervention Type DEVICE

Insertion DUDA device

LEEP

Intervention Type PROCEDURE

Loop Electrosurgical Excision Procedure

Control group

The number of patients to be recruited in this arm will be 120.

Procedure: Loop Electrosurgical Excision Procedure (LEEP) without DUDA device

Group Type ACTIVE_COMPARATOR

LEEP

Intervention Type PROCEDURE

Loop Electrosurgical Excision Procedure

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DUDA device

Insertion DUDA device

Intervention Type DEVICE

LEEP

Loop Electrosurgical Excision Procedure

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* High Grade Cervical Dysplasia, Grades 2 and 3, in the biopsy cervical
* Patient eligible for conization
* Patient must consent for the appropriate surgery
* Patient must have Gynecologic Oncology Group (GOG) performance status of 0, 1
* Patients must have signed an approved informed consent and authorization permitting release of personal health information

Exclusion Criteria

* Pregnancy
* Previous conization
* limited comprehension of the study
* the risk of the American Society of Anesthesiologists, III or IV
* HIV or immunodepression
* Patients with a history of the invasive malignancies
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Barretos Cancer Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ricardo Reis, PHD

Role: STUDY_DIRECTOR

Director of the Teaching and Research Institute - Barretos Cancer Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Barretos Cancer Hospital

Barretos, São Paulo, Brazil

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Brazil

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BarretosCH - DUDA

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.